PLSE

NEUTRALAnalyst

Pulse Biosciences, Inc

2026-09-28

Price

$52.32

+0.95%

This is the 2026-09-28 snapshot — the signals and analysis for PLSE as of this single trading day.

View full PLSE research hub →

Score4.0Watchlist

Signals3/8 DNA1/13 Act · 2/4 Risk

SentimentNEUTRALScore: 8

Volume0.6xvs 20d avg

Analysis

Pulse Biosciences (PLSE) is demonstrating classic High-Conviction Price Discovery, surging over 48% in the past month fueled by recent bullish analyst initiations, including BTIG's $70 price target. In a 'RISK_ON' macro regime where tight credit spreads and a compressing VIX overshadow geopolitical noise, investors are aggressively bidding up idiosyncratic, clinical-stage med-tech stories. The confluence of SURGE and PERFECT_STACK technical signals, alongside low-volume consolidation near recent highs, confirms robust institutional absorption rather than retail exhaustion.

Fired Signals

SURGEGOLDEN CROSSPERFECT STACKINSIDE OUTEXTENSIONDISTRIBUTION

Key Takeaways

Actionable Thesis: PLSE is a high-conviction momentum buy, supported by perfectly aligned moving averages (PERFECT_STACK) and strong institutional sponsorship following recent analyst upgrades.
Key Risk: The company's sky-high valuation relies entirely on clinical execution; any delay in the NANOPULSE-AF pivotal trial or regulatory setbacks will trigger a severe re-rating.
What to Watch: Monitor the $38.17 structural support level and upcoming Q4 updates regarding the completion of U.S. pivotal trial enrollment.

← Back to 2026-09-28 View Full PLSE History →Yahoo Finance &nearr;